NI200900189A - Anticuerpos contra la il-25 - Google Patents

Anticuerpos contra la il-25

Info

Publication number
NI200900189A
NI200900189A NI200900189A NI200900189A NI200900189A NI 200900189 A NI200900189 A NI 200900189A NI 200900189 A NI200900189 A NI 200900189A NI 200900189 A NI200900189 A NI 200900189A NI 200900189 A NI200900189 A NI 200900189A
Authority
NI
Nicaragua
Prior art keywords
antibodies against
interleukin
asthma
bind
antibody
Prior art date
Application number
NI200900189A
Other languages
English (en)
Inventor
Neil James Mckenzie Andrew
Ballantyne Sarah
Original Assignee
Res & Innovation Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res & Innovation Uk filed Critical Res & Innovation Uk
Publication of NI200900189A publication Critical patent/NI200900189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona el anticuerpo 2C3 y miembros de unión a diana basados en 2C3 que se unen a la interleuquina - 25. Estos son útiles en terapia, por ejemplo, el tratamiento del asma.
NI200900189A 2007-04-18 2009-10-16 Anticuerpos contra la il-25 NI200900189A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91247407P 2007-04-18 2007-04-18
GBGB0707505.4A GB0707505D0 (en) 2007-04-18 2007-04-18 Antibodies against il-25

Publications (1)

Publication Number Publication Date
NI200900189A true NI200900189A (es) 2010-09-13

Family

ID=38135020

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900189A NI200900189A (es) 2007-04-18 2009-10-16 Anticuerpos contra la il-25

Country Status (32)

Country Link
US (1) US8206717B2 (es)
EP (1) EP2144934B1 (es)
JP (1) JP5366930B2 (es)
KR (1) KR101605861B1 (es)
CN (1) CN101711256B (es)
AU (1) AU2008240436B2 (es)
BR (1) BRPI0810418A8 (es)
CA (1) CA2684492C (es)
CO (1) CO6260104A2 (es)
CR (1) CR11079A (es)
CY (1) CY1118244T1 (es)
DK (1) DK2144934T3 (es)
EA (1) EA018073B1 (es)
EC (1) ECSP099726A (es)
ES (1) ES2604255T3 (es)
GB (1) GB0707505D0 (es)
GT (1) GT200900271A (es)
HN (1) HN2009003038A (es)
HR (1) HRP20161548T1 (es)
HU (1) HUE030935T2 (es)
IL (1) IL201552A (es)
LT (1) LT2144934T (es)
MX (1) MX2009011234A (es)
MY (1) MY148451A (es)
NI (1) NI200900189A (es)
NZ (1) NZ581178A (es)
PL (1) PL2144934T3 (es)
PT (1) PT2144934T (es)
RS (1) RS55401B1 (es)
SI (1) SI2144934T1 (es)
UA (1) UA100377C2 (es)
WO (1) WO2008129263A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
US8574582B2 (en) * 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
JP5887337B2 (ja) * 2010-03-30 2016-03-16 ヤンセン バイオテツク，インコーポレーテツド ヒト化ｉｌ−２５抗体
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
JP6250351B2 (ja) * 2013-09-30 2017-12-20 シスメックス株式会社 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
EA036658B1 (ru) * 2014-09-23 2020-12-04 Регенерон Фармасьютикалз, Инк. Антитела к il-25 и их применения
IL261802B2 (en) * 2016-03-16 2024-01-01 Abeome Corp Neutralizing monoclonal antibodies to IL-25 and their use
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
US20210332123A1 (en) * 2018-11-19 2021-10-28 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-il-25 antibodies and use thereof
GB202018015D0 (en) 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CN1289668C (zh) * 2003-06-12 2006-12-13 北京安波特基因工程技术有限公司 一种用于抗体改形的体外分子定向进化方法
US8287851B2 (en) 2005-03-08 2012-10-16 Lorus Therapeutics Inc. Use of interleukin 17E for the treatment of cancer
US20070237763A1 (en) 2005-10-06 2007-10-11 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25

Also Published As

Publication number Publication date
IL201552A0 (en) 2010-05-31
UA100377C2 (en) 2012-12-25
GT200900271A (es) 2010-11-03
NZ581178A (en) 2012-01-12
CY1118244T1 (el) 2017-06-28
PT2144934T (pt) 2016-12-02
SI2144934T1 (sl) 2016-12-30
DK2144934T3 (en) 2016-12-12
US20100129380A1 (en) 2010-05-27
US8206717B2 (en) 2012-06-26
CR11079A (es) 2010-03-03
AU2008240436B2 (en) 2011-03-17
KR20100021569A (ko) 2010-02-25
HUE030935T2 (en) 2017-06-28
JP2010524450A (ja) 2010-07-22
IL201552A (en) 2015-08-31
MY148451A (en) 2013-04-30
CA2684492A1 (en) 2008-10-30
JP5366930B2 (ja) 2013-12-11
HRP20161548T1 (hr) 2016-12-30
CN101711256A (zh) 2010-05-19
CN101711256B (zh) 2013-10-16
CA2684492C (en) 2015-11-24
LT2144934T (lt) 2016-12-27
GB0707505D0 (en) 2007-05-30
WO2008129263A1 (en) 2008-10-30
EP2144934A1 (en) 2010-01-20
CO6260104A2 (es) 2011-03-22
HN2009003038A (es) 2011-11-11
MX2009011234A (es) 2010-02-18
ECSP099726A (es) 2010-01-29
EP2144934B1 (en) 2016-08-24
EA200901421A1 (ru) 2010-10-29
ES2604255T3 (es) 2017-03-06
BRPI0810418A8 (pt) 2018-12-11
AU2008240436A1 (en) 2008-10-30
KR101605861B1 (ko) 2016-03-24
PL2144934T3 (pl) 2017-07-31
BRPI0810418A2 (pt) 2014-10-14
EA018073B1 (ru) 2013-05-30
RS55401B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
NI200900189A (es) Anticuerpos contra la il-25
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1121046T1 (el) Στοχευση toy abcb5 για θεραπεια του καρκινου
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
PH12017500890A1 (en) Antibody drug conjugates
NZ709353A (en) Antibodies that bind il-4 and/or il-13 and their uses
TR201817932T4 (tr) Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CO6670524A2 (es) Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
CO6690815A2 (es) Métodos y composiciones para inmunoterapia para enfermedad neural
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
PE20170258A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
NZ717399A (en) Antibodies against csf-1r
EA201400447A1 (ru) АНТИТЕЛА К CD1d